Pharmacoeconomics of New Medications for Common Chronic Ophthalmic Diseases

Survey of Ophthalmology

Volumn 52, Issue 6, 2007, Pages 618-633

  Hirsch, Jan D ^a   Morello, Candis ^a   Singh, Renu ^a   Robbins, Shira L ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

age related macular degeneration; cost effectiveness; cost minimization; cost utility; dry eye disease; economics; glaucoma; pharmacoeconomic analyses

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHAGAN P; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ARTIFICIAL TEAR; BENZOPORPHYRIN DERIVATIVE; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LUBRICATING AGENT; MUSCARINIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PEGAPTANIB; PROSTAGLANDIN DERIVATIVE; RANIBIZUMAB; TIMOLOL; TRAVOPROST; UNCLASSIFIED DRUG; UNOPROSTONE ISOPROPYL ESTER;

COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG COST; DRY EYE; ECONOMIC EVALUATION; EYE DISEASE; GLAUCOMA; HEALTH CARE COST; HEALTH CARE SYSTEM; HOSPITAL COST; HUMAN; HYPOTHESIS; INTRAOCULAR HYPERTENSION; MONOTHERAPY; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PHYSICIAN; PRIORITY JOURNAL; PRODUCTIVITY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY;

CHRONIC DISEASE; COSTS AND COST ANALYSIS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; EYE DISEASES; HUMANS;

EID: 36148932171     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2007.08.017     Document Type: Review

References (68)

1. Ophthalmic cyclosporine (Restasis) for dry eye disease. Med Lett Drugs Ther 45 (2003) 42-43
2. Abelson M.B., Netland P.A., and Chapin M.J. Switching patients with glaucoma or ocular hypertension from dual therapy to monotherapy: evaluation of brimonidine as a model. Adv Ther 18 (2001) 282-297
3. Bateman D.N., Clark R., Azuara-Blanco A., et al. The effects of new topical treatments on management of glaucoma in Scotland: an examination of ophthalmological health care. Br J Ophthalmol 86 (2002) 551-554
4. Bateman D.N., Clark R., Azuara-Blanco A., et al. The impact of new drugs on management of glaucoma in Scotland: observational study. BMJ 323 (2001) 1401-1402
5. Baudouin C., Rouland J.F., and Le Pen C. Changes in medical and surgical treatments of glaucoma between 1997 and 2000 in France. Eur J Ophthalmol 13 Suppl 4 (2003) S53-S60
6. Bernard L.M., Althin R., Dhawan R., et al. Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France. Eur J Ophthalmol 13 Suppl 4 (2003) S30-S43
7. In: Bootman J.L., Townsend R.J., and McGhan W.F. (Eds). Principles of pharmacoeconomics. ed 3 (2005), Harvey Whitney Books Company, Cincinnati, OH
8. Bressler N.M. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 119 (2001) 198-207
9. Brown G.C., Brown M.M., Campanella J., et al. The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration-a value-based reappraisal with 5-year data. Am J Ophthalmol 140 (2005) 679-687
10. Brown G.C., Sharma S., Brown M.M., et al. Utility values and age-related macular degeneration. Arch Ophthalmol 118 (2000) 47-51
11. Christensen T.L., Poulsen P.B., Holmstrom S., et al. A Markov modelled pharmacoeconomic analysis of bimatoprost 0.03% in the treatment of glaucoma as an alternative to filtration surgery in Italy. Curr Med Res Opin 21 (2005) 1837-1844
12. Coons S.J., and Kaplan R.M. Cost utility analysis. In: Bootman J.L., Townsend R.J., and McGhan W.F. (Eds). Principles of Pharmacoeconomics. ed 3 (2005), Harvey Whitney Books Company, Cincinnati, OH 117-148
13. Costagliola C., Parmeggiani F., and Sebastiani A. Assessing the cost-effectiveness of switching from a beta-blocker to latanoprost in the treatment of ocular hypertension. Expert Opin Pharmacother 4 (2003) 1775-1788
14. Cross W.D., Lay L.F., Walt J.G., et al. Clinical and economic implications of topical cyclosporin A for the treatment of dry eye. Manag Care Interface 15 (2002) 44-49
15. Cvetkovic R.S., and Perry C.M. Brinzolamide: a review of its use in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 20 (2003) 919-947
16. Dalzell M.D. Dry eye: prevalence, utilization, and economic implications. Manag Care 12 (2003) 9-13
17. Day D.G., Schacknow P.N., Sharpe E.D., et al. A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther 20 (2004) 383-392
18. Deschaseaux-Voinet C., Lafuma A., and Berdeaux G. Cost and effectiveness of brinzolamide versus dorzolamide in current practice: an analysis based on the UK-GPRD database. J Med Econ 6 (2003) 159-168
19. Fiscella R., and Walt J. Estimated comparative costs of achieving a 20% reduction in intraocular pressure with bimatoprost or latanoprost in patients with glaucoma or ocular hypertension. Drugs Aging 23 (2006) 39-47
20. Fiscella R.G., Green A., Patuszynski D.H., et al. Medical therapy cost considerations for glaucoma. Am J Ophthalmol 136 (2003) 18-25
21. Fry R.N., Avey S.G., and Sullivan S.D. The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard-a Foundation for Managed Care Pharmacy Task Force report. Value Health 6 (2003) 505-521
22. Goldberg L.D., and Walt J. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications. Pharmacoeconomics 24 (2006) 251-264
23. Greiner R.A. Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with verteporfin therapy. Semin Ophthalmol 16 (2001) 218-222
24. Halpern M.T., Covert D.W., and Robin A.L. Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects. Trans Am Ophthalmol Soc 100 (2002) 109-117 discussion 117-8
25. Hirsch J.D. Considerations in the pharmacoeconomics of dry eye. Manag Care 12 (2003) 33-38
26. Holmstrom S., Buchholz P., Walt J., et al. The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries. Curr Med Res Opin 22 (2006) 897-905
27. Hopley C., Salkeld G., and Mitchell P. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration. Br J Ophthalmol 88 (2004) 982-987
28. Hopley C., Salkeld G., Wang J.J., et al. Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants. Br J Ophthalmol 88 (2004) 450-454
29. Kaiserman I., Kaiserman N., Nakar S., et al. The effect of combination pharmacotherapy on the prescription trends of glaucoma medications. J Glaucoma 14 (2005) 157-160
30. Keam S.J., Scott L.J., and Curran M.P. Spotlight on verteporfin in subfoveal choroidal neovascularisation. Drugs Aging 21 (2004) 203-209
31. Keam S.J., Scott L.J., and Curran M.P. Verteporfin: a review of its use in the management of subfoveal choroidal neovascularisation. Drugs 63 (2003) 2521-2554
32. Kobelt G. Health economics, economic evaluation, and glaucoma. J Glaucoma 11 (2002) 531-539
33. Kobelt G., Jonsson B., Bergström A., et al. Cost-effectiveness analysis in glaucoma: what drives utility? Results from a pilot study in Sweden. Acta Ophthalmol Scand 84 (2006) 363-371
34. Kobelt G., and Jönsson L. Modeling cost of treatment with new topical treatments for glaucoma. Results from France and the United Kingdom. Int J Technol Assess Health Care 15 (1999) 207-219
35. Kobelt G., Jönsson L., Gerdtham U., et al. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany. Graefes Arch Clin Exp Ophthalmol 236 (1998) 811-821
36. Kozma C.M., Reeder C.E., and Schulz R.M. Economic, clinical, and humanistic outcomes: a planning model for pharmacoeconomic research. Clin Ther 15 (1993) 1121-1132 discussion 1120
37. Lees M.J., Aldridge G.J., Davey P.J., et al. Economic evaluation of photodynamic therapy with verteporfin. Ophthalmology 110 (2003) 1263-1264 author reply 1264-5
38. Margherio R.R., Margherio A.R., and DeSantis M.E. Laser treatments with verteporfin therapy and its potential impact on retinal practices. Retina 20 (2000) 325-330
39. Meads C., Cummins C., Jolly K., et al. Coronary artery stents in the treatment of ischaemic heart disease: a rapid and systematic review. Health Technol Assess 4 (2000) 1-153
40. Meads C., and Hyde C. Photodynamic therapy with verteporfin is effective, but how big is its effect? Results of a systematic review. Br J Ophthalmol 88 (2004) 212-217
41. Nelson J.D., Helms H., Fiscella R., et al. A new look at dry eye disease and its treatment. Adv Ther 17 (2000) 84-93
42. Noecker R.J., and Walt J.G. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications. Am J Ophthalmol 141 (2006) S15-S21
43. Plosker G.L., and Keam S.J. Bimatoprost: a pharmacoeconomic review of its use in open-angle glaucoma and ocular hypertension. Pharmacoeconomics 24 (2006) 297-314
44. Rechtman E., Ciulla T.A., Criswell M.H., et al. An update on photodynamic therapy in age-related macular degeneration. Expert Opin Pharmacother 3 (2002) 931-938
45. Rouland J.F., Berdeaux G., and Lafuma A. The economic burden of glaucoma and ocular hypertension: implications for patient management: a review. Drugs Aging 22 (2005) 315-321
46. Rouland J.F., and Le Pen C. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 1 year. Eur J Ophthalmol 13 Suppl 4 (2003) S5-S20
47. Rouland J.F., Le Pen C., Benhaddi H., et al. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: Strategies, clinical outcomes, and costs at 2 years. Eur J Ophthalmol 15 (2005) 562-580
48. Rouland J.F., Le Pen C., Gouveia Pinto C., et al. Cost-minimisation study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open-angle glaucoma: in four European countries. Pharmacoeconomics 21 (2003) 201-213
49. Schein O.D., Bressler N.M., and Price P. Photodynamic therapy with verteporfin: observations on the introduction of a new treatment into clinical practice. Arch Ophthalmol 123 (2005) 58-63
50. Schmier J.K., Halpern M.T., and Jones M.L. The economic implications of glaucoma: A literature review. Pharmacoeconomics 25 (2007) 287-306
51. Schmier J.K., Jones M.L., and Halpern M.T. The burden of age-related macular degeneration. Pharmacoeconomics 24 (2006) 319-334
52. Schwartz G.F., and Reardon G. A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension. Surv Ophthalmol 49 (2004) 621-623 author reply 623-4
53. Sharma S., Bakal J., Sharma S.M., et al. Drug pricing for a novel treatment for wet macular degeneration: using incremental cost-effectiveness ratios to ensure societal value. Can J Ophthalmol 40 (2005) 369-377
54. Sharma S., Brown G.C., Brown M.M., et al. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 108 (2001) 2051-2059
55. Shuler M.F., Borrillo J.L., and Ho A.C. Photodynamic therapy update. Curr Opin Ophthalmol 12 (2001) 202-206
56. Smith D.H., Fenn P., and Drummond M. Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case. Br J Ophthalmol 88 (2004) 1107-1112
57. Stewart W.C., Leech J., Sharpe E.D., et al. An economic analysis of switching to latanoprost from a beta-blocker or adding brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular hypertension. Am J Manag Care 8 (2002) S240-S248
58. Stonecipher K., Perry H.D., Gross R.H., et al. The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca. Curr Med Res Opin 21 (2005) 1057-1063
59. Strutton D.R., and Walt J.G. Trends in glaucoma surgery before and after the introduction of new topical glaucoma pharmacotherapies. J Glaucoma 13 (2004) 221-226
60. TAP. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one year results of 2 randomized clinical trials-TAP Report 1. Arch Ophthalmol 117 (1999) 1329-1345
61. Trevithick J., Massel D., Robertson J.M., et al. Model study of AREDS antioxidant supplementation of AMD compared to Visudyne: a dominant strategy?. Ophthalmic Epidemiol 11 (2004) 337-346
62. Tuil E., Hommer A.B., Poulsen P.B., et al. The cost-effectiveness of bimatoprost 0.03% in the treatment of glaucoma in adult patients-a European perspective. Int J Clin Pract 59 (2005) 1011-1016
63. van der Valk R., Schouten J.S., Webers C.A., et al. The impact of a nationwide introduction of new drugs and a treatment protocol for glaucoma on the number of glaucoma surgeries. J Glaucoma 14 (2005) 239-242
64. Ventura M.P., Saheb N.E., Solari H.P., et al. Cost considerations of the new fixed combinations for glaucoma medical therapy. J Clin Pharm Ther 30 (2005) 251-254
65. Vogenberg F.R. Introduction to Applied Pharmacoeconomics (2001), McGraw-Hill Medical Publishing Division, New York
66. Walt J.G., and Lee J.T. A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension. Surv Ophthalmol 49 Suppl 1 (2004) S36-S44
67. Wenkstern A., and Stokes J. Photodynamic therapy in age-related macular degeneration: missing information. Age Ageing 32 (2003) 357-359
68. Wormald R., Evans J., Smeeth L., et al. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev (2003) CD002030